DK3456330T3 - Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer - Google Patents

Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer Download PDF

Info

Publication number: DK3456330T3
Authority: DK; Denmark
Prior art keywords: cortexolon; valerat; 17alpha; tumor treatment; tumor
Prior art date: 2014-10-08

Application number

DK18198653.0T

Other languages

English (en)

Inventor

Mara Gerloni

Original Assignee

Cosmo Technologies Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-08

Filing date

2015-10-07

Publication date

2021-07-26

2015-10-07 Application filed by Cosmo Technologies Ltd filed Critical Cosmo Technologies Ltd

2021-07-26 Application granted granted Critical

2021-07-26 Publication of DK3456330T3 publication Critical patent/DK3456330T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
- C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
- C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

DK18198653.0T 2014-10-08 2015-10-07 Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer DK3456330T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP14188063.3A EP3006453A1 (en)	2014-10-08	2014-10-08	17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
EP15778634.4A EP3204400B1 (en)	2014-10-08	2015-10-07	17a,21-diesters of cortexolone for use in the treatment of tumors

Publications (1)

Publication Number	Publication Date
DK3456330T3 true DK3456330T3 (da)	2021-07-26

Family

ID=51687868

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK15778634.4T DK3204400T3 (da)	2014-10-08	2015-10-07	17alfa,21-diestere af cortexolon til anvendelse i behandling af tumorer
DK18198653.0T DK3456330T3 (da)	2014-10-08	2015-10-07	Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK15778634.4T DK3204400T3 (da)	2014-10-08	2015-10-07	17alfa,21-diestere af cortexolon til anvendelse i behandling af tumorer

Country Status (23)

Country	Link
US (7)	US10183030B2 (da)
EP (4)	EP3006453A1 (da)
JP (5)	JP6503057B2 (da)
KR (4)	KR20230052990A (da)
CN (5)	CN107074905B (da)
AU (3)	AU2015329999B2 (da)
BR (2)	BR112017007078A2 (da)
CA (3)	CA2962746A1 (da)
DK (2)	DK3204400T3 (da)
ES (3)	ES2882223T3 (da)
HR (2)	HRP20190194T1 (da)
HU (2)	HUE055143T2 (da)
IL (3)	IL272095B2 (da)
LT (2)	LT3204400T (da)
MX (3)	MX366294B (da)
PL (2)	PL3204400T3 (da)
PT (2)	PT3456330T (da)
RS (2)	RS62147B1 (da)
RU (3)	RU2712752C2 (da)
SI (2)	SI3204400T1 (da)
TR (1)	TR201901422T4 (da)
WO (2)	WO2016055533A1 (da)
ZA (2)	ZA201702209B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8859774B2 (en)	2012-05-25	2014-10-14	Corcept Therapeutics, Inc.	Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
EP3006453A1 (en)	2014-10-08	2016-04-13	Cosmo Technologies Ltd.	17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
US9943505B2 (en)	2016-09-09	2018-04-17	Corcept Therapeutics, Inc.	Glucocorticoid receptor modulators to treat pancreatic cancer
CA3055076C (en)	2017-03-31	2022-02-22	Corcept Therapeutics, Inc.	Glucocorticoid receptor modulators to treat cervical cancer
WO2020132046A1 (en)	2018-12-19	2020-06-25	Corcept Therapeutics Incorporated	Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CA3121193C (en)	2018-12-19	2024-03-12	Corcept Therapeutics Incorporated	Pharmaceutical formulations containing relacorilant, a heteroaryl-ketone fused azadecalin compound
US11234971B2 (en)	2018-12-19	2022-02-01	Corcept Therapeutics Incorporated	Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
CN110698527B (zh) *	2019-11-19	2022-08-26	湖南新合新生物医药有限公司	一种高纯度氢化可的松-17-戊酸酯的制备方法
CN112028956A (zh) *	2020-09-10	2020-12-04	那路新	合成21-羟基-17-(1-氧代丙氧基)孕甾-4-烯-3,20-二酮的方法
CN114113603B (zh) *	2021-06-30	2023-11-17	四川大学华西医院	Cytl1作为胃癌预后标志物的应用
CN116135871A (zh) *	2021-11-16	2023-05-19	石家庄迪斯凯威医药科技有限公司	一种具有抗耐药性的抗菌化合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1195748B (de) *	1961-06-24	1965-07-01	Vismara Francesco Spa	Verfahren zur Herstellung von 1'-substituierten 17alpha, 21-(1'-Alkoxy)-methylendioxysterioden
BE619180A (fr) *	1961-06-24	1962-12-20	Vismara Francesco Spa	17-monoesters de 17 alpha, 21-dihydroxy stéroïdes et leur procédé de préparation
NL6605514A (da) *	1966-04-25	1967-10-26
DE2748442C3 (de)	1977-10-26	1981-08-27	Schering Ag Berlin Und Bergkamen, 1000 Berlin	17α-(3-Jodbenzoyloxy)-9α -chlor4-pregnen-3.20-dione, Zwischenprodukte und Verfahren zu ihrer Herstellung, 9α -chlor-17α, 21-dihydroxy-1,4-pregnadien-3,20-dion und dieses enthaltende Arzneimittel
EP0001737B1 (de)	1977-10-26	1981-01-07	Schering Aktiengesellschaft	17-Alpha-(3-Jodbenzoyloxy)-9-Alpha-chlor-4-pregnen-3.20-dione, deren D-Homo-analoga und Verfahren zu ihrer Herstellung
ATE12237T1 (de) *	1980-12-23	1985-04-15	Schering Ag	Neue 6-alpha-methylhydrocortison-derivate, ihre herstellung und verwendung.
DE3260474D1 (en)	1981-02-02	1984-09-06	Schering Corp	Aromatic heterocyclic esters of steroids, their preparation and pharmaceutical compositions containing them
US4920216A (en) *	1987-05-28	1990-04-24	The Trustees Of Columbia In The City Of New York	Selective chlorination of steroids and other substrates directed by covalently linked pyridine derivatives acting as templates
US5990099A (en)	1988-10-31	1999-11-23	Alcon Laboratories, Inc.	Angiostatic agents and methods and compositions for controlling ocular hypertension
ES2062528T3 (es)	1989-02-07	1994-12-16	Upjohn Co	Deshalogenacion de compuestos organicos usando estaño o plomo.
DE4121484A1 (de)	1991-06-26	1993-01-07	Schering Ag	Verfahren zur herstellung von 6-methylensteroiden
US6172054B1 (en)	1995-06-15	2001-01-09	Alcon Laboratories, Inc.	Combination therapy for lowering and controlling intraocular pressure
AU3703900A (en)	1999-02-24	2000-09-14	Nitromed, Inc.	Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
ATE251449T1 (de)	1999-06-14	2003-10-15	Cosmo Spa	Geschmacksmaskierte orale pharmazeutische zusammensetzungen mit kontrollierter abgabe
IT1314184B1 (it)	1999-08-12	2002-12-06	Nicox Sa	Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
WO2002040030A1 (en)	2000-11-16	2002-05-23	Alcon Manufacturing, Ltd.	Combination therapy for lowering and controlling intraocular pressure
ITMI20011762A1 (it) *	2001-08-10	2003-02-10	Cosmo Spa	Esteri di 17alfa,21-diidrossipregnene, loro uso come agenti anti-androgenetici e procedimenti per la loro preparazione
ITMI20051695A1 (it) *	2005-09-14	2007-03-15	Cosmo Spa	Uso di 17a-esteri c3-c10 del 9,11-deidrocortexolone cme agenti anti-gonadotropinici
DE102006059063A1 (de)	2005-12-24	2007-06-28	Bayer Healthcare Ag	Verwendung von BAY 59-3074 zur Herstellung von Medikamenten zur Therapie von Hirntumoren sowie Kombinationen von BAY 59-3074
US7687484B2 (en)	2006-05-25	2010-03-30	Bodor Nicholas S	Transporter enhanced corticosteroid activity
ITMI20071616A1 (it) *	2007-08-03	2009-02-04	Cosmo Spa	Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati.
CN101397317A (zh)	2007-09-27	2009-04-01	天津药业研究院有限公司	一种新型硝酸酯类甾体化合物
US20100272717A1 (en) *	2007-12-13	2010-10-28	Novartis Ag	Combinations of therapeutic agents for treating cancer
WO2009117120A1 (en)	2008-03-18	2009-09-24	Sicor Inc.	Purification of air sensitive steroids
CN105785003B (zh) *	2010-06-01	2018-09-07	梅坦诺米克斯保健有限公司	用于在受试者中诊断胰腺癌的工具和方法
US20120245552A1 (en)	2011-03-23	2012-09-27	Pop Test Cortisol Llc	Combination Therapy
RU2506974C1 (ru)	2012-11-06	2014-02-20	Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации	Способ лечения первично нерезектабельного рака легкого
JOP20200097A1 (ar)	2013-01-15	2017-06-16	Aragon Pharmaceuticals Inc	معدل مستقبل أندروجين واستخداماته
EP3006453A1 (en)	2014-10-08	2016-04-13	Cosmo Technologies Ltd.	17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors

2014
- 2014-10-08 EP EP14188063.3A patent/EP3006453A1/en not_active Withdrawn
2015
- 2015-10-07 JP JP2017518340A patent/JP6503057B2/ja active Active
- 2015-10-07 RU RU2017115773A patent/RU2712752C2/ru active
- 2015-10-07 SI SI201530614T patent/SI3204400T1/sl unknown
- 2015-10-07 DK DK15778634.4T patent/DK3204400T3/da active
- 2015-10-07 CA CA2962746A patent/CA2962746A1/en not_active Abandoned
- 2015-10-07 LT LTEP15778634.4T patent/LT3204400T/lt unknown
- 2015-10-07 ES ES18198653T patent/ES2882223T3/es active Active
- 2015-10-07 PL PL15778634T patent/PL3204400T3/pl unknown
- 2015-10-07 KR KR1020237011743A patent/KR20230052990A/ko not_active Application Discontinuation
- 2015-10-07 RU RU2017115771A patent/RU2712950C2/ru active
- 2015-10-07 TR TR2019/01422T patent/TR201901422T4/tr unknown
- 2015-10-07 HU HUE18198653A patent/HUE055143T2/hu unknown
- 2015-10-07 CA CA3160391A patent/CA3160391A1/en active Pending
- 2015-10-07 HU HUE15778634A patent/HUE041503T2/hu unknown
- 2015-10-07 US US15/517,653 patent/US10183030B2/en active Active
- 2015-10-07 EP EP15775455.7A patent/EP3204012B1/en active Active
- 2015-10-07 SI SI201531666T patent/SI3456330T1/sl unknown
- 2015-10-07 CN CN201580060711.0A patent/CN107074905B/zh not_active Expired - Fee Related
- 2015-10-07 CA CA2960928A patent/CA2960928C/en active Active
- 2015-10-07 PT PT181986530T patent/PT3456330T/pt unknown
- 2015-10-07 CN CN202211571443.7A patent/CN116102604A/zh active Pending
- 2015-10-07 BR BR112017007078A patent/BR112017007078A2/pt not_active Application Discontinuation
- 2015-10-07 BR BR112017007076-6A patent/BR112017007076B1/pt active IP Right Grant
- 2015-10-07 KR KR1020177011114A patent/KR102248983B1/ko active IP Right Grant
- 2015-10-07 WO PCT/EP2015/073172 patent/WO2016055533A1/en active Application Filing
- 2015-10-07 KR KR1020217002286A patent/KR102520411B1/ko active IP Right Grant
- 2015-10-07 MX MX2017004660A patent/MX366294B/es active IP Right Grant
- 2015-10-07 RS RS20210928A patent/RS62147B1/sr unknown
- 2015-10-07 US US15/517,659 patent/US10231980B2/en active Active
- 2015-10-07 PL PL18198653T patent/PL3456330T3/pl unknown
- 2015-10-07 RU RU2020102939A patent/RU2020102939A/ru unknown
- 2015-10-07 EP EP15778634.4A patent/EP3204400B1/en active Active
- 2015-10-07 DK DK18198653.0T patent/DK3456330T3/da active
- 2015-10-07 ES ES15778634T patent/ES2713699T3/es active Active
- 2015-10-07 WO PCT/EP2015/073176 patent/WO2016055537A1/en active Application Filing
- 2015-10-07 MX MX2017004661A patent/MX2017004661A/es unknown
- 2015-10-07 AU AU2015329999A patent/AU2015329999B2/en active Active
- 2015-10-07 EP EP18198653.0A patent/EP3456330B1/en active Active
- 2015-10-07 KR KR1020177011239A patent/KR20170063821A/ko unknown
- 2015-10-07 CN CN202010134553.1A patent/CN111285913B/zh active Active
- 2015-10-07 JP JP2017518978A patent/JP6735739B2/ja active Active
- 2015-10-07 CN CN201580060690.2A patent/CN107001406B/zh active Active
- 2015-10-07 ES ES15775455T patent/ES2806094T3/es active Active
- 2015-10-07 RS RS20190207A patent/RS58607B1/sr unknown
- 2015-10-07 CN CN202211425819.3A patent/CN115671114A/zh active Pending
- 2015-10-07 LT LTEP18198653.0T patent/LT3456330T/lt unknown
- 2015-10-07 IL IL272095A patent/IL272095B2/en unknown
- 2015-10-07 AU AU2015330003A patent/AU2015330003A1/en not_active Abandoned
- 2015-10-07 PT PT15778634T patent/PT3204400T/pt unknown
2017
- 2017-03-08 IL IL251028A patent/IL251028B/en active IP Right Grant
- 2017-03-23 IL IL251371A patent/IL251371A0/en unknown
- 2017-03-29 ZA ZA2017/02209A patent/ZA201702209B/en unknown
- 2017-04-07 MX MX2019008063A patent/MX2019008063A/es unknown
2018
- 2018-11-23 US US16/199,015 patent/US10646497B2/en active Active
2019
- 2019-01-17 JP JP2019006199A patent/JP7028809B2/ja active Active
- 2019-01-29 HR HRP20190194TT patent/HRP20190194T1/hr unknown
- 2019-02-12 US US16/273,575 patent/US20190175618A1/en not_active Abandoned
- 2019-04-12 ZA ZA2019/02320A patent/ZA201902320B/en unknown
2020
- 2020-02-27 AU AU2020201446A patent/AU2020201446B2/en active Active
- 2020-03-16 US US16/820,407 patent/US10993949B2/en active Active
- 2020-05-27 JP JP2020092411A patent/JP2020143140A/ja active Pending
- 2020-12-01 JP JP2020199555A patent/JP2021046418A/ja active Pending
2021
- 2021-04-06 US US17/223,776 patent/US11712443B2/en active Active
- 2021-07-22 HR HRP20211177TT patent/HRP20211177T1/hr unknown
2022
- 2022-12-19 US US18/068,346 patent/US20230128438A1/en active Pending

Also Published As

Publication number	Publication date
BR112017007076B1 (pt)	2023-12-19
AU2020201446B2 (en)	2021-03-18
IL251028A0 (en)	2017-04-30
HUE055143T2 (hu)	2021-11-29
DK3204400T3 (da)	2019-03-04
LT3204400T (lt)	2019-04-10
KR102248983B1 (ko)	2021-05-10
MX366294B (es)	2019-07-04
IL272095B2 (en)	2023-04-01
KR20230052990A (ko)	2023-04-20
RU2712950C2 (ru)	2020-02-03
RS62147B1 (sr)	2021-08-31
KR20170063799A (ko)	2017-06-08
EP3204012B1 (en)	2020-06-03
BR112017007078A2 (pt)	2017-12-26
JP2021046418A (ja)	2021-03-25
SI3456330T1 (sl)	2021-09-30
JP2020143140A (ja)	2020-09-10
ZA201702209B (en)	2019-08-28
US10183030B2 (en)	2019-01-22
IL251371A0 (en)	2017-05-29
US20190175618A1 (en)	2019-06-13
JP2019070033A (ja)	2019-05-09
PL3204400T3 (pl)	2019-05-31
AU2020201446A1 (en)	2020-05-14
CN115671114A (zh)	2023-02-03
US11712443B2 (en)	2023-08-01
RU2712752C2 (ru)	2020-01-31
EP3006453A1 (en)	2016-04-13
ES2806094T3 (es)	2021-02-16
CN107074905A (zh)	2017-08-18
CN107001406A (zh)	2017-08-01
US10231980B2 (en)	2019-03-19
US10646497B2 (en)	2020-05-12
RS58607B1 (sr)	2019-05-31
ZA201902320B (en)	2022-11-30
CN107074905B (zh)	2019-08-09
AU2015329999A1 (en)	2017-04-06
HUE041503T2 (hu)	2019-05-28
KR20210012047A (ko)	2021-02-02
CN111285913B (zh)	2023-01-10
CN116102604A (zh)	2023-05-12
WO2016055537A1 (en)	2016-04-14
RU2017115773A3 (da)	2019-03-15
KR20170063821A (ko)	2017-06-08
RU2017115773A (ru)	2018-11-15
LT3456330T (lt)	2021-08-10
MX2017004661A (es)	2017-10-16
US20170360806A1 (en)	2017-12-21
RU2017115771A (ru)	2018-11-12
JP6503057B2 (ja)	2019-04-17
ES2882223T3 (es)	2021-12-01
BR112017007076A2 (pt)	2017-12-26
TR201901422T4 (tr)	2019-02-21
HRP20211177T1 (hr)	2021-10-29
ES2713699T3 (es)	2019-05-23
MX2017004660A (es)	2017-10-16
EP3204400B1 (en)	2018-12-12
EP3456330B1 (en)	2021-05-19
IL272095A (en)	2020-03-31
PT3204400T (pt)	2019-02-25
JP7028809B2 (ja)	2022-03-02
EP3204012A1 (en)	2017-08-16
JP2017530184A (ja)	2017-10-12
US10993949B2 (en)	2021-05-04
AU2015330003A1 (en)	2017-04-13
CN107001406B (zh)	2020-03-27
AU2015329999B2 (en)	2020-01-23
PT3456330T (pt)	2021-07-13
RU2017115771A3 (da)	2019-03-11
US20170304318A1 (en)	2017-10-26
IL251028B (en)	2020-01-30
CN111285913A (zh)	2020-06-16
CA2960928A1 (en)	2016-04-14
EP3456330A1 (en)	2019-03-20
SI3204400T1 (sl)	2019-04-30
IL272095B (en)	2022-12-01
CA3160391A1 (en)	2016-04-14
CA2960928C (en)	2023-10-31
WO2016055533A1 (en)	2016-04-14
HRP20190194T1 (hr)	2019-04-19
US20230128438A1 (en)	2023-04-27
US20210299145A1 (en)	2021-09-30
CA2962746A1 (en)	2016-04-14
EP3204400A1 (en)	2017-08-16
US20190091240A1 (en)	2019-03-28
US20200215080A1 (en)	2020-07-09
PL3456330T3 (pl)	2021-11-15
KR102520411B1 (ko)	2023-04-11
JP6735739B2 (ja)	2020-08-05
MX2019008063A (es)	2019-09-11
RU2020102939A (ru)	2020-05-20
JP2017530171A (ja)	2017-10-12

Publication	Publication Date	Title
DK3288581T3 (da)	2021-01-11	Fremgangsmåde til behandling af cancer
DK3193929T3 (da)	2019-08-19	Behandlingsregimer ved anvendelse af anti-nkg2a-antistoffer
DK3240801T3 (da)	2021-02-08	Kombinationstumorimmunterapi
DK3227262T3 (da)	2020-08-10	Sulfidalkyl og pyridyl-revers-sulfonamidforbindelser til hbv-behandling
DK3185957T3 (da)	2022-08-29	Patisiran til anvendelse ved behandlingen af transthyretin-medieret amyloidosis
DK3186376T3 (da)	2019-05-06	Fremgangsmåder til forbedring af cas9-medieret manipulationseffektivitet
DK3221359T3 (da)	2020-06-22	Fremgangsmåder til tumorbehandling ved anvendelse af CD3XCD20-bispecifikt antistof
DK3167318T3 (da)	2022-06-13	Polarisationsuafhængig behandling ved integreret fotonik
DK3594238T3 (da)	2021-04-19	Antistofsammensætninger til tumorbehandling
DK3110988T3 (da)	2019-07-29	Metoder til behandling af lithiumholdige materialer
DK3389778T3 (da)	2022-09-12	Indretning til fotodynamisk behandling
DK3286311T3 (da)	2021-05-17	Fremgangsmåde til behandling af maligniteter
DK3456330T3 (da)	2021-07-26	Cortexolon-17alpha-valerat til anvendelse ved behandling af tumorer
BR112017011771A2 (pt)	2018-07-10	métodos e composições para o tratamento de câncer
DK3200815T3 (da)	2021-05-10	Fremgangsmåder og sammensætninger til behandling af cancer
DK3231444T3 (da)	2020-03-16	Ny behandling
BR112016022976A2 (pt)	2017-08-15	Métodos para o tratamento de hcv
DE102015102730B8 (de)	2018-08-16	Verbinder
DK3380086T3 (da)	2021-11-22	Cyp26-resistente rar-alpha-selektive agonister i behandling af cancer
DK3374497T3 (da)	2021-11-01	Modificerede makrofager til anvendelse i behandlingen af kræft
DK3302519T3 (da)	2022-02-28	Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
DK3122308T3 (da)	2020-01-13	Indretning til behandling af smerte
DK3253208T3 (da)	2021-06-07	Kombinationsterapier til anvendelse i behandlingen af brystcancer
DK3138583T3 (da)	2019-08-05	Dekontamineringssystem
DK3122349T3 (da)	2022-02-14	Sammensætninger til behandling af autodigestion